<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="fdi:010084610">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="normal" font="default" size="100%">Takalay, S.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Ngo-Giang-Huong, Nicole</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Kongnim, W.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Mongkolwat, P.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Phoseng, P.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Wangsaeng, N.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Hongjaisee, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Butr-Indr, B.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Tragoolpua, K.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Jourdain, Gonzague</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Pornprasert, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Khamduang, W.</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 among at-risk populations in Chiang Mai and Lamphun provinces, Thailand, during November 2020-January 2021</title>
        <secondary-title>PLoS One</secondary-title>
      </titles>
      <pages>e0263127 [12 ]</pages>
      <keywords>
        <keyword>THAILANDE</keyword>
        <keyword>CHIANG MAI PROVINCE</keyword>
        <keyword>LAMPHUN PROVINCE</keyword>
      </keywords>
      <dates>
        <year>2022</year>
      </dates>
      <call-num>fdi:010084610</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>PLoS One</full-title>
      </periodical>
      <isbn>1932-6203</isbn>
      <accession-num>ISI:000775890100049</accession-num>
      <number>2</number>
      <electronic-resource-num>10.1371/journal.pone.0263127</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/fdi:010084610</url>
        </related-urls>
        <pdf-urls>
          <url>https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2022-05/010084610.pdf</url>
        </pdf-urls>
      </urls>
      <volume>17</volume>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <abstract>Non-healthcare workers with a high potential for exposure to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) may contribute to the virus spreading. Data among asymptomatic and high exposure risk populations is still scarce, in particular Chiang Mai and Lamphun provinces, Thailand. We conducted a cross-sectional observational study aiming to assess the prevalence of SARS-CoV-2 RNA positivity, anti-SARS-CoV-2 IgM/IgG, and potential associated factors among asymptomatic/mild symptomatic individuals with a high exposure risk in Chiang Mai and Lamphun provinces, during the second wave of outbreak in Thailand (November 2020-January 2021). Socio-demographic data was collected through an on-line questionnaire prior to collection of nasopharyngeal/throat swab samples and blood samples tested for SARS-CoV-2 RNA (DaAn Gene, China) and anti-SARS-CoV-2 IgM/IgG antibodies (commercial lateral flow immunoassays), respectively. Univariable and multivariable logistic regression analysis were used to analyze associated factors. None of 1,651 participants were found positive for SARS-CoV-2 RNA (0%, 95% confidence intervals, CI: 0-0.2). Fourteen were positive for anti-SARS-CoV-2 IgM/IgG antibodies (0.9%, 95% CI: 0.5-1.4), including 7 positives for IgM and 7 positives for IgG (0.4%, 95% CI: 0.2-0.9). Being over 50 years old was independently associated with virus exposure (OR: 5.8, 95% CI: 1.0-32.1%, p = 0.045). Despite high exposure risk, no current infection was found, and a very high proportion was still susceptible to SARS-CoV-2 infection and would clearly benefit from vaccination. Continuing active surveillance, rolling out of vaccination and monitoring response to vaccine will help better control the COVID-19 spread.</abstract>
      <custom6>052 ; 050</custom6>
      <custom1>UR224 / UR174</custom1>
      <custom7>Thaïlande</custom7>
    </record>
  </records>
</xml>
